Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Continuously Selected in the 'DJSI World,' a Global ESG Investment Index

11/16/2021 | 09:27am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company has been continuously selected as a constituent of 'Dow Jones Sustainability Indices (DJSI) World,' the global version of DJSI, which is the world's leading ESG investment index. Furthermore, Chugai has been selected as a constituent of 'DJSI Asia Pacific,' the Asia-Pacific version, for the seventh time for four consecutive years.

DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA) and is one of the main investment selection criteria for investors worldwide who are interested in corporate sustainability. Companies are selected annually as a constituent based on the sustainability assessment in terms of corporate economic, environmental and social aspects.

In the pharmaceutical sector of the 'DJSI World,' the top eight sustainable companies have been selected as constituents, including Chugai, which received the second-highest sustainability rating among pharmaceutical companies in the world. 322 companies (including 35 Japanese companies) have been selected for the DJSI World in total. Five companies including Chugai, have been selected for 'DJSI Asia Pacific.'

In the growth strategy 'TOP I 2030,' the Company set a 'role model for the world' as one of three visions as a top innovator in 2030. Chugai aims to be recognized for ESG initiatives through its business activities, and become a global role model as a leader in resolving social issues. Since its first selection for DJSI World last year, Chugai's ESG initiatives have evolved further thanks to the PDCA cycle, in which Chugai actively engages in dialogue both inside and outside the Company and uses the feedback to improve our activities. As a result, this year's sustainability scores of occupational health & safety, labor practice and human capital development far exceeded last year. Overall, we have improved our score from last year and received a global top-class sustainability rating.

Chugai's basic management policy is 'creating shared value between our company and society' and 'realize advanced and sustainable medical care centered on patients.' This philosophy is also in line with the 'Sustainable Development Goals (SDGs)' set by the United Nations. Chugai will continue to strive for appropriate disclosure of information on the SDGs and ESG initiatives, create value for patients and society by leveraging innovation that only Chugai can provide, and contribute to solving social issues and building a sustainable society through our business activities.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.24% 3680 Delayed Quote.-1.47%
ROCHE HOLDING AG -1.22% 360.65 Delayed Quote.-4.87%
All news about CHUGAI PHARMACEUTICAL CO., LTD
01/21CHUGAI PHARMACEUTICAL : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia..
PU
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2021 975 B 8 577 M 8 577 M
Net income 2021 292 B 2 569 M 2 569 M
Net cash 2021 461 B 4 056 M 4 056 M
P/E ratio 2021 20,7x
Yield 2021 1,87%
Capitalization 6 051 B 53 179 M 53 211 M
EV / Sales 2021 5,73x
EV / Sales 2022 5,37x
Nbr of Employees 7 555
Free-Float -
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 680,00 JPY
Average target price 4 823,85 JPY
Spread / Average Target 31,1%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.47%53 179
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356